Europe Intra-Articular Injection for Osteoarticular Infiltrations Market is expected to reach US$ 157.08 Million by 2031

Hyaluronic Acid Segment to Lead Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Based on Type During 2023–2031

According to our new research study on “Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Forecast to 2031 – Regional Analysis – by Type, End User, and Country,” the market was valued at US$ 97.43 million in 2023 and is projected to reach US$ 157.08 million by 2031; it is expected to register a CAGR of 6.2% from 2023 to 2031. Key factors driving the market growth include the rising prevalence of osteoarthritis and advancements in injection techniques. However, the side effects associated with intra-articular injections hinder market growth. Nevertheless, the increasing number of clinical trials will enhance the development of innovative products and are projected to bring new Europe intra-articular injection for osteoarticular infiltrations market trends in the coming years.

Osteoarticular disorders include osteoarthritis, rheumatoid arthritis, osteoporosis, lupus arthritis, psoriatic arthritis, and other such conditions. Osteoarthritis is an inflammatory degenerative disease characterized by the deterioration of articular cartilage and underlying bone that predominantly affects the hip and knee. Knee osteoarthritis is a widespread but often challenging problem to manage in primary care. Traditional nonsurgical management, comprising lifestyle modification, physical therapy, and pharmacologic therapy, is often ineffective or leaves residual symptoms. It represents the main cause of disability in those aged 65 or above, and the prevalence of arthritis and chronic joint symptoms increases with age. Osteoarticular and muscular disorders restrict mobility and dexterity, resulting in an early decline of activity, decreased well-being, and often a reduced ability to participate in society. Due to population growth and aging, the number of people with osteoarticular and muscular diseases is rapidly increasing. An infiltration is a procedure that involves injecting a therapeutical substance (mostly a cortisone derivative) into a joint or into the vicinity of an anatomical structure (such as a tendon) with the purpose of reducing pain. This treatment is intended to reduce pain, preserve mobility, and reduce disability, thus enhancing function. Additionally, continuous developments in intra-articular injection for osteoarticular infiltrations, with increasing collaborations and partnerships, contribute to the growing Europe intra-articular injection for osteoarticular infiltrations market size.

Europe Intra-Articular Injection for Osteoarticular Infiltrations Market, by Type, 2023(%)

Source: The Insight Partners Analysis

Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Analysis Based on Segmental Evaluation:

The Europe intra-articular injection for osteoarticular infiltrations market is segmented on the basis of type and end user. Based on type, the market is bifurcated into Type 1 collagen and hyaluronic acid. By end user, the market is segmented into hospitals, orthopedic clinics, and others.

In 2023, the hyaluronic acid segment held a significant Europe intra-articular injection for osteoarticular infiltrations market share. Hyaluronic acid injections are employed to treat knee pain in patients who were not responsive to other treatment options. Viscosupplementation is a newly available choice for patients with symptomatic knee osteoarthritis that involves giving a series of intra-articular injections of hyaluronic acid. Intra-articular administration of hyaluronic acid as an orthobiologic tool is a minimally invasive method that has been proven effective and safe. They are made from either rooster or chicken combs or can be obtained from bacteria and are injected directly into the joint. Knee osteoarthritis is a widespread but often challenging problem to manage in primary care.

Recent advancements in hyaluronic acid injection therapy have significantly expanded growth trajectory. Focus has shifted toward hyaluronic acid-based hydrogel therapeutics, which serve as innovative delivery systems for osteoarthritis treatment. These hydrogels not only improve the biological effects of hyaluronic acid but also have the potential in enhancing joint lubrication, delivering cells, and regenerating damaged tissue. Synvisc, Hyalgan, Orthovisc, Supartz, Eufexxa, Gel-One, and Supartz FX are among the commonly available hyaluronic acid injections, thereby fueling the growth of Europe intra-articular injection for osteoarticular infiltrations market.

A robust focus on developing and introducing novel products in the market is expected to support the growth of the segment, thereby contributing to Europe intra-articular injection for osteoarticular infiltrations market growth. VSY Biotechnology GmbH (Germany) celebrated the 10-year anniversary of Reviscon. In conjunction with this milestone, the company launched Re-Cross, an innovative medical device designed for pain management and the treatment of injury-related inflammatory and osteoarthritic conditions in sports medicine, in May 2024. Re-Cross combines the advantages of linear-designed hyaluronic acid with cross-linked hyaluronic acid molecules through the patented hybrid cross-linking technology HXL, offering an innovative anti-doping solution for athletes worldwide. In addition, Contura International Ltd introduced Arthrosamid, a new hydrogel injection for knee osteoarthritis that harnesses non-biodegradable hydrogel technology, at the British Orthopaedic Association Annual Congress in September 2021.

The scope of the Europe intra-articular injection for osteoarticular infiltrations market report includes the assessment of the market performance in Germany, the UK, France, Italy, Spain, Denmark, and the Rest of Europe. In terms of revenue, Germany held the largest Europe intra-articular injection for osteoarticular infiltrations market share in 2023, and it is estimated to dominate the market during the forecast period. The rising elderly population, growing research and development activities, and advancements in intra-articular injections are the significant factors driving the market.

The Government of Germany invests significantly in healthcare research and infrastructure among all the nations that are a part of the European Union. According to Eurostat, the healthcare expenditure in Germany accounted for US$ 461.15 billion in 2020, one of the highest healthcare expenditures among the relative EU member states. According to the Organization for Economic Cooperation and Development (OECD) Health Statistics, health spending in Germany is growing faster than the actual OECD predicted average. This can be related to the high capital investments dedicated to research and development of better treatment options for people suffering from chronic conditions, which, in turn, supports Europe intra-articular injection for osteoarticular infiltrations market growth.

The presence of various players offering intra-articular injection treatment and conducting clinical trials also favors the market growth in Germany. For instance, in August 2022, Grünenthal (Germany) company enrolled the first patient in its global clinical Phase III trial for resiniferatoxin (RTX). RTX is an intra-articular injection of resiniferatoxin for patients with advanced knee osteoarthritis. The Phase III program included over 1,800 patients with knee osteoarthritis who have tried available treatment options but had no success and continued to suffer from moderate to severe pain. Grünenthal investigated the effectiveness and safety of intra-articular injections of RTX in adults. Ongoing clinical trials are supporting the effectiveness of intra-articular injection treatments, leading to increased physician confidence and recommendations.

Furthermore, in May 2024, VSY Biotechnology GmbH (Germany) introduced its groundbreaking medical device, Re-Cross, aimed at managing pain and addressing inflammatory and osteoarthritic conditions in sports medicine. Re-Cross merges the advantages of linear-designed hyaluronic acid with cross-linked hyaluronic acid molecules, utilizing patented hybrid cross-linking technology HXL, providing an innovative anti-doping solution for athletes globally.

Bioventus Inc., SEIKAGAKU CORPORATION, Maxigen Biotech Inc., ?stem Medical Inc., Sanofi SA, Ferring Pharmaceuticals, Fidia Pharma USA Inc., Biotech Healthcare Group, Bioteck S.p.A., and I+MED are among the leading companies profiled in the Europe intra-articular injection for osteoarticular infiltrations market report.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com